- Report
- April 2025
- 200 Pages
Global
From €4029EUR$4,490USD£3,467GBP
- Report
- October 2024
- 182 Pages
Global
From €3181EUR$3,545USD£2,738GBP
€3534EUR$3,939USD£3,042GBP
- Report
- June 2024
- 185 Pages
Global
From €4038EUR$4,500USD£3,475GBP
- Report
- July 2019
- 165 Pages
Global
From €4442EUR$4,950USD£3,823GBP
- Report
- January 2024
- 150 Pages
Global
From €4352EUR$4,850USD£3,746GBP
- Report
- November 2023
- 182 Pages
Global
From €3229EUR$3,599USD£2,779GBP
- Report
- March 2025
- 74 Pages
Global
From €3500EUR$4,178USD£3,118GBP
- Report
- September 2024
- 74 Pages
Global
From €3500EUR$4,178USD£3,118GBP
- Report
- April 2025
- 50 Pages
Global
From €2378EUR$2,650USD£2,047GBP
- Book
- July 2023
- 1568 Pages
Diclazuril is an animal pharmaceutical used to treat coccidiosis, a parasitic disease that affects the gastrointestinal tract of animals. It is a benzeneacetonitrile derivative, and is used in the form of a suspension or a paste. It is used to treat a variety of animals, including poultry, swine, and cattle. Diclazuril is effective in controlling the spread of coccidiosis, and is also used to prevent the disease from occurring.
The diclazuril market is a growing sector of the animal pharmaceuticals industry. It is used to treat a wide range of animals, and is becoming increasingly popular due to its effectiveness in controlling the spread of coccidiosis. The market is expected to continue to grow in the coming years, as more and more farmers and veterinarians turn to diclazuril to treat their animals.
Some companies in the diclazuril market include Elanco Animal Health, Merck Animal Health, Zoetis, and Bayer Animal Health. These companies produce and distribute diclazuril products to veterinarians and farmers around the world. Show Less Read more